Avoid common mistakes on your manuscript.
Dear Editor,
Natural killer (NK) cell lymphoma, or extranodal NK/T-cell lymphoma, nasal type, according to the World Health Organization classification, is a rare neoplasm affecting preferentially Asian and South American populations, being extremely unusual in Western patients [1]. There are two clinical forms, nasal and non-nasal (extranasal) [2]. In nasal NK-cell lymphoma, the nasal and upper aerodigestive areas are initially involved. Dissemination to the skin, gut, testis, salivary glands or marrow occurs in advanced diseases. In non-nasal NK-cell lymphomas, however, the skin, gut, testis, salivary glands or marrow are the primary sites. Non-nasal NK-cell lymphomas have been reported to have a worse prognosis [3].
A 59-year-old man presented with bone pain, jaundice and fever. There were no lymphadenopathy or organomegaly. Investigations showed hemoglobin: 11.4 g/dL, white cell count: 1.4 × 109/L with no abnormal circulating cells, platelet count: 45 × 109/L, bilirubin: 67 (7–19) μmol/L, alkaline phosphatase: 510 (49–138) U/L, alanine aminotransferase: 407 (6–53) U/L, aspartate aminotransferase: 336 (13–33) U/L and lactate dehydrogenase (LDH): 1,200 (107–218) U/L. A positron emission tomography/computerized tomography (PET/CT) showed hyper-metabolic lesions confined exclusively to the bone marrow (Fig. 1a). Histologic examination of the marrow showed diffuse infiltration by medium-sized lymphoid cells with irregular nuclei, clumped chromatin and cytoplasm with fine azurophilic granules, associated with florid hemophagocytosis (Fig. 1b). The neoplastic cells were surface CD3–, CD2+, CD7+, CD56+, and strongly positive for Epstein Barr virus encoded RNA on in situ hybridization (Fig. 1c). A nasal panendoscopy showed normal nasal, nasopharyngeal and oropharyngeal areas. Overall features were consistent with non-nasal NK-cell lymphoma.
He was treated with methotrexate 2 g/m2 (day 1), and ifosamide 1.5 g/m2/day, etoposide 100 mg/m2/day, dexamethasone 40 mg/day (days 2 to 4) [4]. He responded with normalization of temperature and LDH. On day 8, however, he developed fever, nasal pain and obstruction with epistaxis. A CT scan showed a 2-cm rim-enhancing irregular lesion in the nasopharynx, a site which was uninvolved initially (Fig. 1d). Biopsy of the lesion confirmed NK-cell lymphoma infiltration (Fig. 1e). Treatment with L-asparaginase (6,000U/m2/alternate daily × 7) induced complete resolution of symptoms. Following normalization of blood counts and liver function, a marrow examination showed complete morphologic remission. Nasal panendoscopy with random nasopharyngeal biopsies also showed normal findings.
Although NK-cell lymphomas are considered aggressive [1], stage I/II nasal NK-cell lymphomas have a favorable prognosis with radiotherapy and chemotherapy [5], whereas stage III/IV nasal NK-cell lymphomas fare much worse with few survivors. Conversely, non-nasal NK-cell lymphomas at any stage have been reported to have uniformly poor prognoses [3]. An important caveat in diagnosing non-nasal NK-cell lymphoma is that few if any studies of these patients actually examined the nasal areas carefully with panendoscopy, random biopsies or state-of-the-art imaging techniques. Therefore, many “non-nasal” NK-cell lymphomas might conceivably represent in fact disseminated nasal NK-cell lymphomas, particularly when the primary sites of “non-nasal” NK-cell lymphomas are precisely the sites where nasal NK-cell lymphomas will metastasize to. This is well illustrated in our patient, who would have been diagnosed to have a “non-nasal” NK-cell lymphoma, because even an initial thorough examination with PET/CT scan and pan-endoscopy, a rigorous evaluation absent in any of the previous studies of “non-nasal” NK-cell lymphomas [3], did not show nasal involvement. The subsequent rapid appearance of a nasopharyngeal lesion highly suggested that there was initial occult nasal involvement undetectable despite stringent investigations. Therefore, unless results from pathologic, biologic or molecular studies indicate otherwise, “nasal” and “non-nasal” NK-cell lymphomas should be considered different clinical forms of the same disease process.
References
Chan JK, Jaffe ES, Ralfkiaer E (2001) Extranodal NK/T-cell lymphoma, nasal type. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds) Tumours of haematopoietic and lymphoid tissues. IARC, Lyon, pp 204–207
Kwong YL (2005) Natural killer-cell malignancies: diagnosis and treatment. Leukemia 19:2186–2194 doi:10.1038/sj.leu.2403955
Chan JK, Sin VC, Wong KF, Ng CS, Tsang WY, Chan CH et al (1997) Nonnasal lymphoma expressing the natural killer cell marker CD56: a clinicopathologic study of 49 cases of an uncommon aggressive neoplasm. Blood 89:4501–4513
Yamaguchi M, Suzuki R, Kwong YL, Kim WS, Hasegawa Y, Izutsu K et al (2008) Phase I study of dexamethasone, methotrexate, ifosfamide, L-asparaginase, and etoposide (SMILE) chemotherapy for advanced-stage, relapsed or refractory extranodal natural killer (NK)/T-cell lymphoma and leukemia. Cancer Sci 99:1016–1020 doi:10.1111/j.1349-7006.2008.00768.x
Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R et al (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216–221 doi:10.1182/blood-2003-05-1401
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Tse, E., Leung, R., Khong, PL. et al. Non-nasal natural killer cell lymphoma: not non-nasal after all. Ann Hematol 88, 185–187 (2009). https://doi.org/10.1007/s00277-008-0562-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-008-0562-0